Opinion

Video

Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

Author(s):

Catherine C. Coombs, MDMatthew S. Davids, MD, MMSc

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

Video content above is prompted by the following:

  • BGB-16673
Related Videos
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
Bradley McGregor, MD, director, clinical research, Lank Center for Genitourinary Oncology, Marra Lochiatto Investigator, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Reid Merryman, MD
A panel of 5 experts on CLL
Grzegorz S. Nowakowski, MD
Emre Yekedüz, MD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
Related Content
Susan L. Slager, PhD
September 10th 2024

Mayo Clinic Study Finds Dysfunctional White Blood Cells Linked to Heightened Melanoma Risk

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Jacob Sands, MD, of Dana-Farber Cancer Institute
September 9th 2024

Dato-DXd Misses OS End Point in TROPION-Lung01 Study for NSCLC

Ravi Salgia, MD, PhD, professor, chair, Department of Medical Oncology & Therapeutics Research, Arthur & Rosalie Kaplan Chair in Medical Oncology & Therapeutics Research, City of Hope
September 2nd 2024

Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

Radhika Bansal, MBBS, postdoctoral fellow, Mayo Clinic
September 9th 2024

Real-World Outpatient CAR T-Cell Administration Insights Show Improved Safety and Feasibility in NHL

William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features